IRadimed Corporation (IRMD) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IRadimed Corporation (IRMD), Healthcare sektöründe faaliyet gösteriyor, son olarak 99.17$'dan işlem görüyor ve 2B piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 48/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 9 Şub 2026IRadimed Corporation (IRMD) Sağlık ve Boru Hattı Genel Bakışı
IRADIMED CORPORATION is a leader in MRI-compatible medical devices, offering innovative solutions like the MRidium IV infusion pump and patient vital signs monitoring systems, ensuring patient safety and clinical efficiency in MRI environments, and boasting a strong 26.3% profit margin.
Yatırım Tezi
IRADIMED CORPORATION presents a notable research candidate due to its leadership position in the niche market of MRI-compatible medical devices. The increasing demand for MRI procedures, coupled with the growing awareness of patient safety in MRI environments, drives the need for IRADIMED's specialized products. The company's high gross margin of 77.1% and a profit margin of 26.3% demonstrate strong profitability and efficient operations. The company's dividend yield of 1.23% provides a steady return. Key growth catalysts include expanding the product portfolio with innovative MRI-compatible devices and accessories, penetrating new international markets, and leveraging the company's established sales and distribution network. With a market capitalization of $1.22 billion and a P/E ratio of 57.63, IRADIMED offers a unique blend of growth potential and financial stability in the healthcare sector.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $1.22B reflects investor confidence in IRADIMED's market position and growth prospects.
- P/E ratio of 57.63 indicates a premium valuation, reflecting expectations of future earnings growth.
- Profit Margin of 26.3% demonstrates strong profitability and efficient cost management.
- Gross Margin of 77.1% highlights the company's pricing power and value proposition in the specialized MRI-compatible medical device market.
- Dividend Yield of 1.23% provides a consistent return to shareholders, enhancing the investment appeal.
Rakipler & Benzerleri
Güçlü Yönler
- Specialization in MRI-compatible medical devices.
- Strong gross and profit margins.
- Established brand reputation.
- Proprietary technology and intellectual property.
Zayıflıklar
- Limited product diversification.
- Reliance on a niche market.
- High P/E ratio may indicate overvaluation.
- Relatively small size compared to larger medical device companies.
Katalizörler
- Upcoming: Launch of new MRI-compatible medical devices and accessories in Q3 2026.
- Ongoing: Expansion into new international markets, particularly in Asia and Europe.
- Ongoing: Increasing adoption of MRI-guided interventions in hospitals and imaging centers.
- Ongoing: Strategic partnerships with leading healthcare providers and research institutions.
Riskler
- Potential: Competition from larger medical device companies with greater resources.
- Potential: Technological advancements that could render existing products obsolete.
- Potential: Changes in regulatory requirements that could increase compliance costs.
- Ongoing: Economic downturns that could reduce healthcare spending and impact sales.
- Ongoing: Dependence on a niche market, making the company vulnerable to changes in MRI technology or clinical practices.
Büyüme Fırsatları
- Expanding the Product Portfolio: IRADIMED has the opportunity to develop and launch new MRI-compatible medical devices and accessories to address unmet clinical needs. This includes exploring innovative solutions for patient monitoring, drug delivery, and surgical procedures within the MRI environment. The market for MRI-compatible devices is estimated to grow significantly over the next five years, driven by the increasing adoption of MRI-guided interventions. By investing in research and development, IRADIMED can capture a larger share of this expanding market and solidify its leadership position.
- Penetrating New International Markets: IRADIMED can expand its geographic reach by entering new international markets with a growing demand for MRI procedures. This includes targeting countries in Asia, Europe, and Latin America, where healthcare infrastructure is developing and access to advanced medical imaging technologies is increasing. By establishing strategic partnerships with local distributors and healthcare providers, IRADIMED can navigate regulatory hurdles and establish a strong presence in these emerging markets. This international expansion will diversify the company's revenue streams and reduce its reliance on the US market.
- Leveraging the Established Sales and Distribution Network: IRADIMED can leverage its existing sales and distribution network to promote and sell its products to a wider customer base. This includes strengthening relationships with hospitals, acute care facilities, and outpatient imaging centers, as well as expanding its reach to new customer segments, such as research institutions and academic medical centers. By providing comprehensive training and support to its sales team, IRADIMED can enhance its ability to educate healthcare providers about the benefits of its MRI-compatible devices and drive sales growth.
- Strategic Acquisitions and Partnerships: IRADIMED can pursue strategic acquisitions and partnerships to expand its product offerings, access new technologies, and enter new markets. This includes targeting companies with complementary product lines or expertise in areas such as medical imaging, patient monitoring, or drug delivery. By integrating these acquisitions and partnerships, IRADIMED can create synergies and enhance its competitive position in the MRI-compatible medical device market. These strategic moves can accelerate the company's growth trajectory and create long-term value for shareholders.
- Increasing Awareness and Education: IRADIMED can invest in marketing and educational initiatives to raise awareness of the importance of MRI-compatible medical devices and the benefits of its products. This includes participating in industry conferences, publishing scientific articles, and conducting webinars and training programs for healthcare providers. By educating the market about the risks associated with using non-compatible devices in MRI environments, IRADIMED can drive demand for its safe and effective solutions and establish itself as a thought leader in the field.
Fırsatlar
- Expanding product portfolio with new MRI-compatible devices.
- Penetrating new international markets.
- Strategic acquisitions and partnerships.
- Increasing awareness and education about MRI safety.
Tehditler
- Competition from larger medical device companies.
- Technological advancements that could render existing products obsolete.
- Changes in regulatory requirements.
- Economic downturns that could reduce healthcare spending.
Rekabet Avantajları
- Specialized Expertise: Deep understanding of MRI compatibility requirements.
- Regulatory Approvals: FDA clearances and other regulatory approvals create barriers to entry.
- Brand Reputation: Established reputation for safety and reliability in MRI environments.
- Customer Relationships: Strong relationships with hospitals and imaging centers.
IRMD Hakkında
IRADIMED CORPORATION, founded in 1992 and headquartered in Winter Springs, Florida, is a global leader in the development, manufacture, and distribution of magnetic resonance imaging (MRI) compatible medical devices. The company's core mission is to provide safe and effective solutions for patients undergoing MRI procedures, addressing the critical need for medical devices that can operate safely within the powerful magnetic fields of MRI scanners. IRADIMED's flagship product is the MRidium MRI compatible intravenous (IV) infusion pump system, designed to deliver medication and fluids safely and accurately during MRI scans. This system includes associated disposable IV tubing sets, ensuring a closed and sterile fluid pathway. The company also offers an MRI compatible patient vital signs monitoring system, which allows clinicians to continuously monitor a patient's physiological parameters, such as heart rate, blood pressure, and oxygen saturation, throughout the MRI procedure. Beyond these core products, IRADIMED provides a range of complementary accessories, including non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. These products are sold through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors, targeting hospitals, acute care facilities, and outpatient imaging centers both in the United States and internationally. IRADIMED's commitment to innovation and patient safety has established it as a trusted partner for healthcare providers seeking to enhance the quality and safety of MRI-guided care.
Ne Yaparlar
- Develops MRI-compatible intravenous (IV) infusion pump systems.
- Manufactures MRI-compatible patient vital signs monitoring systems.
- Offers disposable IV tubing sets for use with its infusion pumps.
- Provides non-magnetic IV poles for MRI environments.
- Supplies wireless remote displays and controls for medical devices.
- Offers side car pump modules and dose error reduction systems.
- Provides SpO2 monitoring solutions with sensors and accessories.
İş Modeli
- Sells MRI-compatible medical devices and accessories to hospitals and imaging centers.
- Generates revenue from the sale of disposable IV tubing sets.
- Provides maintenance and repair services for its installed base of medical devices.
- Offers training and support services to healthcare providers.
Sektör Bağlamı
IRADIMED CORPORATION operates within the medical device industry, specifically focusing on MRI-compatible devices. The global medical device market is experiencing steady growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements in medical imaging. The demand for MRI procedures is rising, creating a greater need for devices that can safely operate within MRI environments. IRADIMED differentiates itself through its specialization in MRI compatibility, a critical safety requirement. Competitors like AHCO, AXGN, CRON, CTEV, and GDRX operate in the broader medical device market, but do not have the same specialization.
Kilit Müşteriler
- Hospitals and acute care facilities.
- Outpatient imaging centers.
- Research institutions.
- Academic medical centers.
Finansallar
Grafik & Bilgi
IRadimed Corporation (IRMD) hisse senedi fiyatı: $99.17 (-0.03, -0.03%)
Son Haberler
-
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
zacks.com · 23 Mar 2026
-
Iradimed Insider Sold Shares Worth $762,971, According to a Recent SEC Filing
MT Newswires · 18 Mar 2026
-
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
globenewswire.com · 16 Mar 2026
-
Why The IRADIMED (IRMD) Story Is Shifting As Analysts Update Targets And Guidance Arrives
Yahoo! Finance: IRMD News · 13 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
IRMD için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $120.00
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, IRMD'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
Iradimed Insider Sold Shares Worth $762,971, According to a Recent SEC Filing
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
Why The IRADIMED (IRMD) Story Is Shifting As Analysts Update Targets And Guidance Arrives
IRMD Hakkında Sıkça Sorulan Sorular
IRMD için değerlendirilmesi gereken temel faktörler nelerdir?
IRadimed Corporation (IRMD) şu anda yapay zeka skoru 48/100, düşük puanı gösteriyor. Hisse 56.3x F/K oranıyla işlem görüyor, S&P 500 ortalamasının (~20-25x) üzerinde, yüksek büyüme beklentilerine işaret ediyor. Analist hedefi $120.00 ($99.17'dan +21%). Temel güçlü yan: Specialization in MRI-compatible medical devices.. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device companies with greater resources.. Bu bir finansal tavsiye değildir.
IRMD MoonshotScore'u nedir?
IRMD şu anda MoonshotScore'da 48/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
IRMD verileri ne sıklıkla güncellenir?
IRMD fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler IRMD hakkında ne diyor?
Analistler, IRMD için $120.00 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($99.17) yukarı yönlü %21 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
IRMD'a yatırım yapmanın riskleri nelerdir?
IRMD için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device companies with greater resources.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. 56.3x F/K oranıyla, büyüme beklentileri karşılanamazsa değerleme riski taşıyor. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
IRMD'ın P/E oranı nedir?
IRadimed Corporation (IRMD)'nın son P/E oranı 56.3, ki bu da piyasa ortalamasının üzerinde, bu da yüksek büyüme beklentilerini gösterebilir. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.
IRMD aşırı değerli mi, yoksa düşük değerli mi?
IRadimed Corporation (IRMD)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 56.3. Analist hedefi $120.00 (mevcut fiyattan +21%), analistlerin yukarı yönlü potansiyel gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
IRMD'ın temettü verimi nedir?
IRadimed Corporation (IRMD) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is based on the most recent available information.
- Future performance is subject to market conditions and company-specific factors.